[HTML][HTML] Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
A tale of two antibodies: obinutuzumab versus rituximab
CL Freeman, LH Sehn - British journal of haematology, 2018 - Wiley Online Library
While rituximab has dramatically improved outcomes for patients with CD20+ malignancies
for two decades, responses are not universal and resistance can develop. Obinutuzumab …
for two decades, responses are not universal and resistance can develop. Obinutuzumab …
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
A Younes, J Brody, C Carpio… - The Lancet …, 2019 - thelancet.com
Background Preclinical studies have shown synergistic antitumour effects between ibrutinib
and immune-checkpoint blockade. The aim of this study was to assess the safety and activity …
and immune-checkpoint blockade. The aim of this study was to assess the safety and activity …
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
TJ Kipps, H Eradat, S Grosicki, J Catalano… - Leukemia & …, 2015 - Taylor & Francis
We evaluated the safety and biologic activity of the BH3 mimetic protein, navitoclax,
combined with rituximab, in comparison to rituximab alone. One hundred and eighteen …
combined with rituximab, in comparison to rituximab alone. One hundred and eighteen …
Anti-CD20 monoclonal antibodies: reviewing a revolution
JML Casan, J Wong, MJ Northcott… - Human vaccines & …, 2018 - Taylor & Francis
Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have
revolutionised the treatment of B cell hematological malignancies and have become a …
revolutionised the treatment of B cell hematological malignancies and have become a …
Ocrelizumab in relapsing and primary progressive multiple sclerosis: pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
E Gibiansky, C Petry, F Mercier… - British journal of …, 2021 - Wiley Online Library
Aims Ocrelizumab is a humanized monoclonal antibody that selectively targets CD20‐
positive B cells and is indicated for treatment of patients with relapsing forms of multiple …
positive B cells and is indicated for treatment of patients with relapsing forms of multiple …
Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report
M Tout, O Casasnovas, M Meignan… - Blood, The Journal …, 2017 - ashpublications.org
High variability in patient outcome after rituximab-based treatment is partly explained by
rituximab concentrations, and pharmacokinetic (PK) variability could be influenced by tumor …
rituximab concentrations, and pharmacokinetic (PK) variability could be influenced by tumor …
Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
J Golay, G Semenzato, A Rambaldi, R Foà, G Gaidano… - MAbs, 2013 - Taylor & Francis
The anti-CD20 antibody rituximab (RTX; Rituxan®, MabThera®) was the first anti-cancer
antibody approved by the US Food and Drug Administration in 1997 and it is now the most …
antibody approved by the US Food and Drug Administration in 1997 and it is now the most …
Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non‐Hodgkin's lymphoma and exposure–response in CLL
E Gibiansky, L Gibiansky, DJ Carlile… - CPT …, 2014 - Wiley Online Library
Treatment regimens involving obinutuzumab (GA101) demonstrated increased efficacy to
rituximab in clinical trials for non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic …
rituximab in clinical trials for non‐Hodgkin's lymphoma (NHL) and chronic lymphocytic …
Pharmacokinetic parameters of infliximab influence the rate of relapse after de‐escalation in adults with inflammatory bowel diseases
A Petitcollin, C Brochard, L Siproudhis… - Clinical …, 2019 - Wiley Online Library
This study aimed at exploring the link among individual concentrations, pharmacokinetic
parameters, and the probability of relapse after de‐escalation in a real‐world prospective …
parameters, and the probability of relapse after de‐escalation in a real‐world prospective …